Target intelligence / Profile preview

T helper 17 differentiation pathway components (Th17 pathway)

Target
Th17 pathway
Molecular classification
Transcription factor, Cytokine, Receptor, Kinase
01

Overview

The T helper 17 (Th17) differentiation pathway components represent a complex network of cytokines, receptors, and transcription factors responsible for the development and effector functions of Th17 cells. Key components include the master transcription factor ROR-gamma-t, the signaling protein STAT3, and cytokines such as IL-6, IL-23, and TGF-beta which drive differentiation, as well as IL-17A, IL-17F, and IL-22 which mediate the downstream inflammatory response. This pathway is essential for host defense against extracellular bacteria and fungi at mucosal surfaces but is frequently dysregulated in autoimmune and chronic inflammatory diseases. Therapeutic strategies targeting this pathway include monoclonal antibodies that neutralize IL-17 or IL-23, and small molecule inhibitors targeting JAK kinases or ROR-gamma-t. While highly effective in treating conditions like psoriasis and spondyloarthritis, modulation of this pathway requires careful monitoring due to the increased risk of specific opportunistic infections and potential impacts on intestinal barrier integrity.

Other names
Th17 cell differentiationIL-17 signaling pathwayROR-gamma-t signalingIL-23/IL-17 axis
02

Mechanism of action

Inhibition of Th17-promoting cytokines (IL-23, IL-6), blockade of Th17-produced cytokines (IL-17A, IL-17F), or inhibition of intracellular signaling molecules (JAK/STAT, ROR-gamma-t) to prevent Th17 cell expansion and pro-inflammatory activity.

03

Biological functions

Immune responseCell differentiationSignal transductionInflammationHost defense against extracellular pathogens
04

Disease associations

PsoriasisPsoriatic arthritisAnkylosing spondylitisCrohn's diseaseUlcerative colitisMultiple sclerosisRheumatoid arthritis
05

Safety considerations

Increased risk of fungal infections (e.g., Candidiasis)Increased risk of upper respiratory tract infectionsExacerbation of inflammatory bowel disease (specifically with IL-17 inhibitors)NeutropeniaSuicidal ideation (noted with Brodalumab)
06

Interacting drugs

Secukinumab

8 more in the full profile.

07

Biomarkers

IL-17A levelsIL-17F levelsIL-22 levelsRORC (ROR-gamma-t) expressionSTAT3 phosphorylation

Beyond the preview

Go deeper on T helper 17 differentiation pathway components (Th17 pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T helper 17 differentiation pathway components (Th17 pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call